Our findings emphasize the potential of the HMGA2 associated HOTAIR axis as a prognostic biomarker and therapeutic target, especially in ER negative, postmenopausal onset, and relapsed breast cancer. This evidence concerns the gene HOTAIR and breast carcinoma.